Retrophin, Inc.
Mar 7, 2017

Retrophin to Present at the Barclays Global Healthcare Conference

SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET.

A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for at least 30 days.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.

Retrophin.com

Contact:

Chris Cline, CFA

Senior Director, Investor Relations

646-564-3680            

IR@retrophin.com

Primary Logo

Source: Retrophin, Inc.

News Provided by Acquire Media